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Human cytomegalovirus (HCMV) genome and related proteins have been reported in a great proportion of malignant gliomas.
However, these results are unexpected since HCMV is not known as an oncogenic virus. By immunohistochemistry (with an anti-IE1
monoclonal antibody) and in situ hybridisation (with biotinylated DNA probes) on tissue microarrays and frozen sections, we
investigated a French series of central nervous system (CNS) tumours, including 97 glioblastomas. In 10 cases of glioblastoma, rare
astrocyte-like cells, admixed with tumour cells, stained positively for HCMV and in one case a doubtful staining of rare cells was
noticed. This may indicate a reactivation of the virus under local immunosuppression but none of the cases of CNS tumours
(n¼132) contained HCMV genomes and/or proteins in a significant proportion of tumour cells. Our results strongly suggest that
HCMV is unlikely to be implicated in the development of human malignant gliomas, at least in French cases.
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A viral aetiology for human central nervous system (HCNS)
tumours is provocative and remains a matter of strong debates.
However, the discovery of a viral implication in CNS tumorigenesis
may open different ways for preventing tumours with a constant
fatal outcome such as glioblastomas. Accumulating data seem to
indicate that SV40 is implicated in different tumours in humans
and in particular in central nervous system (CNS) (Bergsagel
et al, 1992; Klein et al, 2002; Carbone et al, 2003; Vilchez and Butel,
2003) However, there are strong controversies as to whether
SV40 is directly linked to cancer development and a consensus is
far from being reached in particular in lymphoma (Shivapurkar
et al, 2002; Vilchez et al, 2002; Capello et al, 2003; MacKenzie
et al, 2003).
A recent study has implicated the HCMV in the pathogenesis of
malignant gliomas (Cobbs et al, 2002). HCMV is a b-herpesvirus
able to infect various types of human cells, including glial cells
(Britt and Alford, 1996). As other herpesviruses, HCMV infects
70–90% of the adult human population and persists in reservoir
cells (Britt and Alford, 1996). Interestingly, in certain circum-
stances (immunosuppression), HCMV can be reactivated, thus
undergoing a lytic cycle (Britt and Alford, 1996). However, except
for non-Hodgkin’s lymphoma, the incidence of primary CNS
tumours is not increased in immunosuppressed patients. More-
over, despite recent investigations demonstrating the presence of
HCMV in prostate and colorectal cancers (Harkins et al, 2002;
Samanta et al, 2003), as yet this virus is not recognised as an
oncogenic factor, at least in vivo.
In this study, we sought to detect HCMV infection in a series
of French cases of CNS tumours by combining immunohisto-
chemistry (IHC) and in situ hybridisation (ISH) on tissue
microarrays.
MATERIAL AND METHODS
Tissues samples
Cases of CNS tumours were retrieved from our files at the Purpan
Hospital in Toulouse between 1988 and 2003. Most cases were
processed routinely, that is, fixed in Bouin’s liquid and/or in 10%
buffered formalin before paraffin embedding. These tumours
consisted of 15 ependymomas, 81 glioblastomas and 20 oligoden-
drogliomas prepared in two blocks of tissue microarray (TMA)
(Beecher Instruments, Micro-array technology, Sun Prairie, WI,
USA). The age of the patients was between 31 and 87 years. Frozen
material was available for nine patients with glioblastoma (among
the 81 cases selected in tissue microarray). Six additional cases of
glioblastoma from Toulouse (not included in the TMA) and 10
cases of glioblastoma from the University Hospital of Limoges
were investigated because of the availability of frozen material. The
approval of the French equivalent of the Institutional Review
Board (Comite ´ Consultatif de Pre ´servation des Personnes en
Recherche Biologique/CCPPRB) is not required for investigations
based on archived paraffin and frozen blocks that have been
routinely used for diagnostic purposes.
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One anti-HCMV monoclonal antibody (clone E13, Argene-Biosoft,
Varihes, France) was used in this study. It recognises an immediate
early antigen of HCMV (IE1) and does not crossreact with EBV,
Adenovirus, VZV and HSV. It works very well in positive controls
(working dilution 1:100) and gives a strong nuclear staining in
tissues with active HCMV infection (Figure 1). In addition, a weak
cytoplasmic staining is seen in virtually all infected cells. In
parallel, antigen retrieval and amplification with catalysed system
amplification (CSA) (Dako, Carpintera, CA, USA) were used. This
latter technique is on the order of 50-fold greater in sensitivity
compared to standard IHC. The staining of the positive controls
was obtained after standard antigen retrieval and/or amplification
of the signal by CSA.
Immunostaining on paraffin sections was performed using the
method described elsewhere with little modifications (Brousset
et al, 2001). Briefly, paraffin sections were mounted on glass slides
coated with silane (Sigma chemical Co., Saint Quentin, France).
Sections were deparaffinised, placed in 10mmoll
 1 Na-citrate
buffer (pH.6), and heated in a microwave oven (Whirlpool model;
Philips, Eindhoven, Holland) at 900W for cycles of 20 and 10min.
The slides were removed from the oven and allowed to cool for
30min at room temperature. After washing in water, endogenous
peroxidase was blocked with 1% hydrogen peroxide in methanol
for 30min. Slides were then rinsed in PBS before staining
with a streptavidin–biotin three-stage technique, with the DAKO
Strept ABC complex/HRP Duet kit (DAKO, code No. K492). For
CSA technique, we used the kit from DAKO according to the
supplier’s recommendations. The DAKO CSA system HRP is an
extremely sensitive immunohistochemical staining procedure
incorporating a signal amplification method based on the
peroxidase-catalysed deposition of a biotinylated compound
followed by a secondary reaction with streptavidin peroxidase
(DAKO). Immunostaining on frozen sections was performed
according the alkaline phosphatase antialkaline phosphatase
(APAAP) technique without prior antigen reactivation (Cordell
et al, 1984). The working dilution of the antibody was identical to
that of paraffin sections.
Positive controls consisted of lung biopsies (autopsy) of two
HIV-positive patients and three colon biopsies (endoscopy) of
nonimmunocompromised patients. Negative controls consisted of
10 normal (hyperplastic) lymph nodes and two cases of Hodgkin’s
disease. All these cases have been processed routinely, that is, fixed
in Bouin’s liquid and paraffin embedded. Frozen autopsy tissues of
different organs from an immunocompromised patient (bone
marrow transplantation) with generalised HCMV infection have
also been included as positive controls.
In addition to anti-IE1 (E13) antibody, an anti-p52 ((non-
structural early DNA-binding protein (UL44 reading frame))
antibody (clone CCH2, Dako) was applied to frozen sections of
the 10 additional cases from Limoges, with the same APAAP
technique.
In situ hybridization
This technique has been described elsewhere (Brousset et al, 1992).
A biotinylated DNA probe from a commercial source (Enzo,
PathoGene DNA probe assay, CMV DNA probe Pack, Part No
32802, Enzo life Sciences Inc., Faimingdale, NY, USA) was used
according to the manufacterer’s recommendations with some
modifications (Brousset et al, 1992). In our hands, we found a
correlation between ISH and IHC for control tissues.
RESULTS
Human cytomegalovirus was detectable by IHC with or without
amplification in all control tissues included in this study. The
signal was strong, nuclear more or less cytoplasmic and was absent
Figure 1 Immunodetection of HCMV with anti-IE1 (E13) antibody in a
patient with acute colitis (peroxidase,  500).
Figure 2 (A, B) Patterns of HCMV infection in two cases of
glioblastoma. Note a strong positive nuclear and weak cytoplasmic staining
with E13 Ab in isolated cells (peroxidase,  800).
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the tissue processing on the results. We found a correlation
between IHC and ISH for control tissues. In the series of 116 cases
of CNS tumours, including 81 glioblastomas, we found HCMV-
positive cells by IHC in only nine cases of glioblastoma,
corresponding to isolated astrocyte like cells (one or two
cells per slice). These cells were difficult to identify as reactive or
neoplastic because of the possible modifications induced by
viral infection (Figure 2A and B). No signs of endothelial cell
infection were noticed. In these nine tumours and in all
other tumours, we did not find HCMV infection in a significant
proportion of cancer cells by both IHC (with and without
amplification) and ISH. In nine cases of glioblastoma for
which frozen material was available in Toulouse, we found
scattered positive cells in one case only. This latter case had the
same staining pattern on paraffin sections, whereas one case with
positive cells on paraffin sections remained completely negative on
frozen sections. The remaining cases were negative with both IHC
methods. The six additional cases from Toulouse, not included in
the TMA, were completely negative with anti-IE1. The 10 cases
from Limoges were also negative with both anti-IE1 and anti-p52
antibodies despite a doubtful cytoplasmic staining of rare cells in
one case.
Only seven out of the nine cases undoubtedly positive by IHC
were detected by ISH (five different slices for all cases).
DISCUSSION
The report by Cobbs et al (2002) is the first to show that HCMV
nucleic acids and proteins are present in a high percentage of low-
and high-grade malignant gliomas. In addition, they found the
expression of early and delayed HCMV gene products in the
tumours. The authors stated that their data did not establish a
causal role for HCMV in glioma pathogenesis, but at least that
HCMV could facilitate glioma progression through clonal expan-
sion without producing a productive or cytopathic viral infection
(Cobbs et al, 2002).
Our results roughly based on the same approach indicate that
HCMV can be reactivated in scattered cells and in only a few cases
of human gliomas. The presence of replicative viral genome and
lytic proteins suggests that HCMV is reactivated, possibly under
local immunosuppression. The site of its replication corresponds
to a priori glial cells, the benign or malignant status of which could
not be determined. These data are clearly at variance with those of
Cobbs et al (2002). In addition, if HCMV had some role in CNS
oncogenesis, one would expect to find the virus in all tumours cells
as the result of a clonal expansion secondary to early infection by
the virus. Our data do not support this hypothesis. In addition, an
increased incidence of glial tumours and the description of
HCMV-related tumours have not been reported in immunosup-
pressed patients.
The tissues we used in this study were mainly fixed in Bouin’s
liquid, which is well known to degrade nucleic acids (principally
RNA). For these reasons, we did not use the RNA probe designed
by Cobbs et al (2002). Indeed, most of mRNAs are degraded after
Bouin’s fixation. However, the use of a biotinylated DNA probe
appears more suitable in this setting and has proven to be sensitive
enough to detect HCMV genomes in cases with active viral
replication (as suggested by IE1 expression). The latter idea was
reinforced by the good correlation between IHC and ISH.
However, the lack of perfect correlation between IHC and ISH
can be easily explained by the scarcity of positive cells in each case
(one or two per slices). One level in the block (one slice) can
contain one or two positive cells but such cells could be absent in
the next levels. The same explanation can be proposed to explain
the discrepancy observed between fixed and frozen tissues.
Nevertheless, the most reliable and the simplest technique for
detecting HCMV on fixed or frozen tissue sections is IHC with
anti-IE1 antibodies. In their study, Cobbs et al (2002) have used
this approach and we have confirmed that HCMV IE1 could be
detected in some cases of glial tumours. However, contrary to the
Cobbs et al’s (2002) study, the virus was mainly located in isolated
cells suggesting a sporadic reactivation. The lack of IE1 detection
in tumour cells on frozen sections is in keeping with the data
obtained on paraffin sections. Interestingly, in 10 cases, the same
results were obtained with the anti-p52 (CCH2) antibody. Since we
used a reliable immunohistochemical technique (including signal
amplification by CSA), our results can be compared with those of
Cobbs et al (2002). We have no clue to understand the discrepancy
of the results but epidemiological variations can be put forward to
explain the difference of incidence of HCMV infection in glial
tumours in France.
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